Form 10-K BRAINSTORM CELL THERAPEU For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Brainstorm Cell Therapeutics (BCLI) Tops Q4 EPS by 8c; Net R&D Expenses Halved
March 10, 2016 7:55 AM ESTBrainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q4 EPS of ($0.07), $0.08 better than the analyst estimate of ($0.15).
Net R&D expenses for the fourth quarter of 2015 were $0.8 million, compared with $1.6 million for the fourth quarter of 2014.
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
... More